HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia.

AbstractOBJECTIVES:
To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia.
METHODS:
Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or donepezil 10 mg/day (n = 32, after 5 mg/day) for 24 weeks. Our primary endpoints were change from baseline to weeks 12 and 24 in the Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) and the Korean version of neuropsychiatric inventory (K-NPI).
RESULTS:
A total of 24 patients received donepezil completed the study (mean age = 72.0 + 7.5 K-Mini-Mental State Examination [MMSE] = 21.0 + 5.1). After 12 weeks and 24 weeks, patients showed improvements in cognitive function on the SNSB-D compared baseline of 16.29 points at 12 weeks (P < .05) and 12.44 points at 24 weeks (P < .05). Significant improvements were shown in only memory domain, immediate verbal recall and delayed recall tests. Subgroup with better cognitive function (SNSB-D > 100) were more effective in frontal and memory domains than the other subgroup (SNSB-D < 100). Withdrawal rates due to adverse events were very low (4.16%).
CONCLUSIONS:
Donepezil-treated patients with Binswanger type subcortical vascular dementia demonstrated significant improvement in cognition compared with baseline, and donepezil was well tolerated.
AuthorsJay Cheol Kwon, Eung Gyu Kim, Jae Woo Kim, Oh Dae Kwon, Bong Goo Yoo, Hyon Ah Yi, Nack Cheon Choi, Seon Young Ahn, Byung Hwa Lee, Myong Jin Kang, Dae Seob Choi, BKVD Study Group
JournalAmerican journal of Alzheimer's disease and other dementias (Am J Alzheimers Dis Other Demen) 2009 Aug-Sep Vol. 24 Issue 4 Pg. 293-301 ISSN: 1938-2731 [Electronic] United States
PMID19383979 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Indans
  • Nootropic Agents
  • Piperidines
  • Donepezil
Topics
  • Aged
  • Aged, 80 and over
  • Cognition (drug effects)
  • Cognition Disorders (drug therapy, pathology)
  • Dementia, Vascular (drug therapy, pathology)
  • Donepezil
  • Female
  • Follow-Up Studies
  • Humans
  • Indans (administration & dosage, adverse effects)
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Nootropic Agents (administration & dosage, adverse effects)
  • Piperidines (administration & dosage, adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: